FDA Approves Boston Scientific's Express LD Iliac Stent System

March 11, 2010—Boston Scientific Corporation (Natick, MA) announced that the US Food and Drug Administration has approved its Express LD iliac premounted stent system for use in iliac arteries.

According to the company, the Express LD iliac stent is designed to be highly deliverable, and its Tandem Architecture stent design is engineered to balance strength, flexibility, and conformability. The company said that it plans to launch the product immediately in the United States. The Express LD iliac stent has also received CE Mark approval and is currently approved for use in the iliac arteries in a number of international markets, the company advised.

“Boston Scientific's Express LD iliac stent incorporates a flexible stent design and is engineered for improved deployment accuracy, two critical treatment components,” commented Barry T. Katzen, MD. “With an approved iliac indication, the Express LD stent offers physicians a less-invasive alternative to surgery for our patients with iliac artery disease.”

Luc Stockx, MD, added, “I have found that the benefits of a balloon-expandable stent like the Express LD iliac stent can be extremely important when working in atherosclerotic iliac lesions. Deployment accuracy and radial strength can play crucial roles in these types of procedures, and the Express LD stent is designed to deliver both.”